Today, Oncode Accelerator announced that ExpediteBio, a biotechnology company dedicated to accelerating the development, de-risking the progression, and enabling the early clinical validation of innovative antibody-based therapeutics, has joined its Biologics Workstream as a new partner. The collaboration strengthens Oncode Accelerator's ability to move promising anti-cancer antibody-based therapeutics from the lab bench towards first-in-human studies.
